4.5 Article

Seasonal influenza and vaccination coverage

Journal

VACCINE
Volume 28, Issue -, Pages D33-D44

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.08.027

Keywords

Seasonal influenza vaccination; Universal vaccination; Vaccination of healthy children; Vaccination guidelines; Vaccination strategy; Europe; USA

Funding

  1. Sanofi Pasteur

Ask authors/readers for more resources

Seasonal influenza represents a considerable public health burden, and annual vaccination represents the most effective preventive strategy for amelioration of this problem. Certain groups are at greatest risk, such as the young, the elderly, pregnant women, and those with chronic underlying medical conditions: the high-risk groups. Traditionally, annual vaccination has been targeted to people classified as being at high risk, particularly the elderly, but in recent years, there has been a broadening of vaccination recommendations to target larger numbers of people. This has recently culminated in the recommendation of universal vaccination in the USA (everyone over 6 months of age is recommended to receive the seasonal influenza vaccine). In this review, we will look at coverage rates in Europe and the USA, changes in vaccination guidelines, and the rationale for broadening vaccination recommendations. It is clear that often only modest improvements in vaccination coverage have occurred recently, with programs targeting risk groups, hut some substantial increases in coverage have followed the broadening of USA vaccination recommendations to all persons under 18 years and to middle-aged healthy adults (>= 50 years). It is likely, however, that some of these increases may be because of the increased awareness related to the recent pandemic. It is unclear if increases in coverage will translate into public health benefits, but perhaps results will be similar to experiments with universal vaccination in Ontario, Canada, where increased coverage may have provided some reductions in healthcare use, fewer influenza-associated deaths, and even financial benefits. (c) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available